Bibliographic Details
| Title: |
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G) |
| Authors: |
Sakai, Daisuke, Taniguchi, Hiroya, Sugimoto, Naotoshi, Tamura, Takao, Nishina, Tomohiro, Hara, Hiroki, Esaki, Taito, Denda, Tadamichi, Sakamoto, Takeshi, Okuda, Hiroyuki, Satoh, Taroh, Tsushima, Takahiro, Makiyama, Akitaka, Tsuda, Takashi, Hosokawa, Ayumu, Kuramochi, Hidekazu, Tokunaga, Shinya, Moriwaki, Toshikazu, Yasui, Hisateru, Ishida, Hiroyasu, Tsuji, Akihito, Otsu, Satoshi, Shimokawa, Hozumi, Baba, Eishi, Sato, Mikio, Matsumoto, Shigemi, Ozaki, Yukinori, Shinozaki, Katsunori, Tamagawa, Hiroshi, Goto, Masahiro, Kadowaki, Shigenori, Fujii, Hirofumi, Koh, Yasuhiro, Yamazaki, Kentaro, Hironaka, Shuichi, Kishimoto, Junji, Boku, Narikazu, Hyodo, Ichinosuke, Muro, Kei |
| Source: |
In European Journal of Cancer August 2020 135:11-21 |
| Database: |
ScienceDirect |
